Antonio Costanzo, CEO of Curaleaf International, has been in the cannabis industry for five years.
It is not the case in the United States and Canada, where their standards are lower than the pharmaceutical ones and specific for the cannabis industry.
In those countries where medical cannabis products are not yet reimbursable, we can sell them at a lower price than the average price of the illegal cannabis sold in the black market.
However, we think to provide more product formulations soon, including tablets, creams, gel, and vaping devices.
But this will take time as cannabis is a complex plant, as we have to understand how all compounds work and interact with each other.
However, Curaleaf International has managed, along with Italian medical cannabis distributor Farmalabo, to register one of our extracts as an in Italy.
The European Commission have recently validated a synthetic CBD novel food application submitted by Italian company Farmabios, who partnered up with us some months ago.
European countries will move forward regardless of what is happening in North America, even if the United States, Canada, and Uruguay have paved the way to legalization.